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Abstract
INVESTIGATING THE EFFECTS OF PSILOCYBIN ON MODELS OF ANXIETY,
RECOGNITION MEMORY, AND DEPRESSION-LIKE BEHAVIOR AND THE ROLE OF
THE 5-HT2A RECEPTOR IN MEDIATING PSILOCYBIN’S IMPACT ON BEHAVIORAL
DESPAIR
By Nikita Thakur
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science
in Physiology and Biophysics at Virginia Commonwealth University
Virginia Commonwealth University, 2022
Director: Javier González-Maeso, Ph.D.
Professor
Department of Physiology and Biophysics
Psychedelics are a class of hallucinogenic substances that exert their effects through
serotonin (5-HT) receptor agonism, particularly at the 5-HT2 receptor, which is further
characterized into the 2A, 2B, and 2C subtypes. While some research studies indicate that
psychedelics mediate their effects via 5-HT2A receptor agonism, others show that it is not
necessary to induce these effects. Recently, there has been a growing interest in psychedelicassisted therapy as a promising alternative for treatment of anxiety and depression, two of the
most common psychiatric disorders worldwide associated with significant morbidity. Although
antidepressants and pharmacological interventions for anxiety have revolutionized management,
they often have mixed efficacy and fail to provide satisfactory emotional relief. Clinical studies
show that psychedelics like psilocybin and LSD produce antidepressant and anxiolytic effects,
but there is still an active debate on whether or not these effects are mediated via action at the 5HT2A receptor.
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In this study, my first aim was to examine psilocybin’s effects on the following
behavioral assays in male WT C57BL/6 mice: head-twitch response (HTR), a 5-HT2A-specific
rodent model of hallucinogenic action; locomotor activity, a model of anxiety; novel object
recognition (NOR), to assess recognition memory; light-dark box preference, an additional
model of anxiety; and forced swim test (FST), a model of depression-like behavior. HTR
assessed the acute effects of psilocybin, while the remaining assays measured psilocybin’s postacute effects (i.e. 24 hrs following administration). Second, I aimed to determine whether or not
psilocybin’s post-acute antidepressant-like effects are mediated by the 5-HT2A receptor by
conducting FST assays using the 5-HT2A-specific antagonist volinanserin (M100,907). Acutely,
psilocybin evoked a greater HTR relative to the vehicle group, but post-acutely it did not produce
a significant difference in locomotion, NOR, or light-dark exploratory behavior. However, mice
given psilocybin in the first FST had both lower immobility and higher climbing times relative to
controls. In the second FST, mice administered M100,907 shortly before injection with
psilocybin exhibited no significant difference in immobility and climbing times compared to
controls. Interestingly, in the third FST, mice given M100,907 alone had a significantly lower
climbing time, while immobility and swimming times between the vehicle and experimental
groups were nonsignificant. The results of this study suggest that the 5-HT2A receptor may
indeed play a central role in mediating psychedelics’ post-acute effects, and that antagonizing it
impairs these effects. These findings highlight the need for additional studies that examine the
post-acute effects of a variety of psychedelics and further investigate the level of involvement of
the 5-HT2A receptor using genetically modified animal models.

x

Chapter 1: Introduction
Psychedelics
Psychedelics are psychoactive substances that affect mood, perception, thought, and
numerous other cognitive processes. They are also known as classic serotonergic hallucinogens,
as they exert their effects through brain serotonin 2A (5-HT2A) receptors (Nichols, 2016).
Although classification systems may vary, in general there are three categories of psychedelics
based on biochemical and behavioral characteristics: ergolines, phenethylamines, and
tryptamines (Winter, 2009). While lysergic acid diethylamide (LSD) is classified as an ergoline
(Nichols, 2004), it is important to note that its structure contains both a phenethylamine and the
indole nucleus common to tryptamines. The phenethylamine hallucinogens include mescaline,
2,5-dimethoxy-4-methylamphetamine (DOM), and 2,5-dimethoxy-4-iodoamphetamine (DOI).
Those belonging to the tryptamine class include N,N-dimethyltryptamine (DMT), 5-methoxyN,N-dimethyltryptamine (MDMT), psilocybin (found in “magic” mushrooms), and its active
derivative psilocin (Winter, 2009).
Although the realm of hallucinogenic research is relatively young, historical records
indicate that psychedelics have been used for thousands of years and were frequently employed
by early cultures in sociocultural and ritualistic practices. However, the introduction of
psychedelics into modern research began in 1943, when Swiss chemist Albert Hoffman
accidentally discovered LSD and its powerful psychological effects. Not long after, serotonin
was discovered in the mammalian brain, and the tryptamine moiety in LSD was found to be the
scaffold for serotonin’s chemical structure (Nichols, 2016). Hoffman’s discovery was followed
by significant investigations of the therapeutic applications of LSD, psilocybin, mescaline, and
other psychedelic substances for various psychiatric illnesses (Belouin & Henningfield, 2018).
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A. 5-hydroxytryptamine

B. Lysergic acid diethylamide

Figure 1: Comparison of the chemical structures of serotonin and LSD. Both (A) 5hydroxytryptamine (serotonin) and (B) lysergic acid diethylamide (LSD) contain the
tryptamine moiety, suggesting that LSD functions in the brain via interaction with a
serotonin receptor. ChemDraw Professional 21.0.

Serotonin Hypothesis of Psychedelic Action
Following the discovery of LSD’s similar chemical and pharmacological profiles to
serotonin (Fig. 1), there was an increasing interest in understanding the role of serotonin (5-HT)
in behavior. Initially, Gaddum et al. (1953) found that LSD antagonized the effects of 5-HT in
peripheral tissues. Specifically, whereas 5-HT induced vasoconstriction and bronchoconstriction
in perfused cat lungs, LSD abolished these effects. LSD was also shown to antagonize the effects
of 5-HT on rat uterus (Gaddum et al., 1953). This evidence of LSD’s antimetabolite action on
smooth muscle, in addition to its structural similarities to 5-HT, led Woolley and Shaw (1954) to
propose that LSD induces altered mental states because of its antagonism of 5-HT action in the
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brain. Furthermore, they inferred that if LSD can produce alternate states of consciousness by
interfering with serotonin, then serotonin supposedly plays an important role in maintaining
normal mental processes (Woolley & Shaw, 1954).
As cited in Nichols and Nichols (2008), Shaw and Woolley later modified their original
inference, since subsequent assays performed two years later showed that LSD could mimic the
effects of 5-HT. For instance, LSD was found to stimulate clam heart and cause an increase in
the amplitude of the beat, similar to 5-HT. Additionally, LSD acted like 5-HT in raising the
blood pressures of anesthetized dogs, suggesting that it may be a 5-HT receptor agonist (Shaw &
Woolley, 1956). Eventually, it was determined that LSD primarily functions as an agonist at 5HT receptors, and that its hallucinogenic effects are mediated through this action. The serotonin
hypothesis of psychedelic action was expanded to include psychedelic substances of other
classes, such as mescaline and psilocin (Aghajanian & Marek, 1999).

5-HT2A Receptor as a Primary Target of Psychedelics
In 1957, Gaddum and Picarelli reported the existence of two different 5-HT receptor
subtypes from their studies in the guinea pig ileum. They characterized these subtypes as D and
M, since they could be blocked with dibenzyline and morphine, respectively (Gaddum &
Picarelli, 1957). However, it was not until the mid-1970s when additional 5-HT receptors were
identified in mammalian brain samples using newly developed radioligand binding techniques
(Peroutka & Snyder, 1979). Following the extensive development of molecular biological
techniques, additional 5-HT receptor subtypes were discovered during the 1980s up through the
beginning of the 1990s. Currently, there are 14 structurally and pharmacologically distinct
mammalian 5-HT receptors arranged into seven families. With the exception of the 5-HT3
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receptor (a ligand-gated ion channel), all 5-HT receptors are G protein-coupled receptors
(GPCRs) (Barnes & Sharp, 1999).
The GPCRs are a superfamily of receptors with a common motif of seven transmembrane
alpha helices (comprised of hydrophobic amino acids) that couple with heterotrimeric GTPbinding proteins, or G proteins. Although initially divided into three classes, GPCRs are now
categorized into six receptor families based on sequence and function: A (rhodopsin), B
(secretin), C (metabotropic glutamate), D (fungal mating pheromone), E (cAMP), and F (frizzled
and smoothened) (Basith et al., 2018). Intracellular signaling through GPCRs occurs upon
binding of the appropriate ligand, which activates the G protein. G proteins are composed of 𝛼,
𝛽, and 𝛾 subunits, where the 𝛼 and 𝛽𝛾 subunits are responsible for signaling. There are different
signaling cascades depending on the specific type of G protein associated with a receptor. For
instance, Gs is stimulatory, Gi/o is inhibitory, and Gq/11 is stimulatory but also results in a
downstream increase in intracellular calcium concentration (Alexander et al., 2011).
Of the 5-HT receptors, the 5-HT2 receptor family in particular has been shown to mediate
the hallucinogenic effects of psychedelics. The 5-HT2R family comprises three different receptor
subtypes: 5-HT2A, 5-HT2B, and 5-HT2C (Alexander et al., 2011). In several drug discrimination
assays, pretreatment of rats with the 5-HT2R antagonists ketanserin and pirenperone blocked the
discriminative stimulus effects of the psychedelic DOM. These antagonists were also effective in
preventing DOM-stimulus generalization to mescaline and LSD (Glennon et al., 1983).
Moreover, subsequent studies found a strong correlation between 5-HT2R binding affinity in rat
cortical tissues and human hallucinogenic potency for various psychedelic substances (Glennon
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et al., 1984). Eventually, the focus of research shifted to the 5-HT2A receptor (5-HT2AR) as
being the necessary component in generating hallucinogenesis and mediating related behavioral
responses in animal models (López-Giménez & González-Maeso, 2018). The 5-HT2AR, like all
members of the 5-HT2 receptor family, is a class A GPCR that is Gq/11-coupled. This pathway
activates phospholipase C and produces inositol triphosphate (IP3) and diacylglycerol (DAG),
ultimately increasing intracellular calcium levels (McCorvy & Roth, 2015).
Several important studies highlighted the involvement of 5-HT2AR in inducing
psychedelics’ effects. In the mid-1990s, Fiorella et al. indicated that antagonists blocking the
effects of psychedelics were more selective for the 5-HT2A receptor as opposed to the 5-HT2C
receptor. Additionally, the 5-HT2A selective antagonist volinanserin (M100,907), but not the 5HT2C selective antagonist SB 200,646A, was shown to block the effects of the psychedelic DOI
in rats (Fiorella et al., 1995). 5-HT2AR was also found to play a role in head-twitch response
(described in a later section), a rodent behavior often expressed in response to 5-HT receptor
agonists. In this study, DOI was injected bilaterally into the medial prefrontal cortex of rats to
induce head-twitches. Pretreatment with the 5-HT2A antagonists ketanserin and M100,907
inhibited DOI-induced head-twitches, but not in rats pretreated with a selective 5-HT2C/2B
antagonist (Willins & Meltzer, 1997). Another study by González-Maeso et al. (2003) used
genetically modified animal models to confirm that DOI- and LSD-induced head-twitches
present in wild-type mice are abolished in 5-HT2AR null-mutant mice. Intriguingly, a 1998 study
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in humans showed that psilocybin-induced psychotomimetic effects were blocked by ketanserin
and the atypical antipsychotic risperidone (Vollenweider et al., 1998). Not only was this data
consistent with previous animal studies, but it also served as the first evidence in humans of 5HT2AR’s central role in generating hallucinogenic effects.

Clinical Applications of Psychedelics
Depression and anxiety are two of the most common psychiatric disorders worldwide and
are both associated with significant morbidity. In the United States alone, approximately 8.4% of
adults reported having at least one major depressive episode in 2020 (National Institute of
Mental Health, 2022). Anxiety disorders are the most common mental illness in the U.S.,
affecting about 18.1% of the population every year (Anxiety and Depression Association of
America, 2021).
The DSM-5 diagnostic criteria for major depressive disorder (MDD) include: depressed
mood; loss of interest or pleasure (anhedonia); significant weight loss (when not dieting) or
weight gain; insomnia or hypersomnia; fatigue; feelings of worthlessness, or excessive or
inappropriate guilt; diminished ability to think or concentrate; and recurrent thoughts of death or
suicidal ideation, or a suicide attempt. For an MDD diagnosis, five or more of these symptoms
must be present nearly every day during the same two-week period, with at least one being
depressed mood or anhedonia (American Psychiatric Association, 2013). While there are
multiple types of anxiety disorders, generalized anxiety disorder (GAD) is more common in the
U.S. GAD is characterized by excessive anxiety or worry often associated with: restlessness or
fatigue, irritability, muscle tension, or difficulty concentrating. According to the DSM-5, these
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symptoms must persist for at least six months to receive a diagnosis (American Psychiatric
Association, 2013).
While the discovery of antidepressant therapy transformed the management of
depression, up to 60% of patients remain inadequately treated. This can be attributed to several
factors, such as non-compliance following undesirable side effects, the drugs’ delayed
therapeutic effect, or an inherent non-responsiveness to the drugs. Likewise, pharmacological
and psychosocial interventions used for anxiety have mixed efficacy and often fail to provide
satisfactory emotional relief to patients (Muttoni et al., 2019). Recently, there has been a growing
interest in psychedelic-assisted therapy as a promising alternative for treatment of these
disorders.
Research indicates that amygdala hyperactivity is associated with depressive symptoms,
and antidepressant therapy normalizes its function (Sladky et al., 2015). As 5-HT receptor
agonists, psychedelics like psilocybin have been found to enhance amygdala inhibition, which
correlates with an increase in positive mood (Kraehenmann et al., 2015). Psychedelics may also
act by modulating glutamatergic neurotransmission via 5-HT2AR agonism (Moreno et al., 2011).
Higher levels of cortical glutamate concentration indirectly increase brain-derived neurotrophic
factor (BDNF) expression, which is associated with increased neurogenesis and neuroplasticity
(Vollenweider & Kometer, 2010). Brain imaging has shown that patients with depression exhibit
deficient neurogenesis and downregulation of neurotrophic activity. Therefore, restoration of
normal BDNF levels with the help of psychedelics could have a therapeutic effect (Duman,
2004). In addition to their neurobiological mechanisms, psychedelics elicit personally
meaningful and spiritually significant experiences conducive to their therapeutic potential
(Griffiths et al., 2006). In fact, clinical trials with psilocybin have shown that up to 87% of
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participants attribute an increased life satisfaction or wellbeing to this psychospiritual
experience. Moreover, at the 6.5-month follow-up, psilocybin was associated with enduring
anxiolytic and antidepressant effects (Ross et al., 2016).
Overall, psychedelics have been shown to induce post-acute therapeutic effects by
modulating neural circuits implicated in mood and affective disorders via 5-HT receptor agonism
(Fig. 2) and by evoking profound psychospiritual experiences (Muttoni et al., 2019).
Incorporating psychedelics to create a new approach for treating depression and anxiety could
potentially help patients who suffer debilitating side effects or are unresponsive to conventional
methods.
On the contrary, there have been a few studies suggesting that these effects of
psychedelics may not be 5-HT2AR-dependent. For instance, using chronically stressed male
mice, Hesselgrave et al. (2021) found that a single dose of psilocybin reversed anhedonic
responses assessed with the sucrose and female urine preference tests while also strengthening
excitatory synapses in the hippocampus. However, pretreatment with the 5-HT2AR antagonist
ketanserin did not prevent these behavioral or electrophysiological responses to psilocybin
(Hesselgrave et al., 2021). Another study found that while ketanserin pretreatment 10 min prior
to administration of psilocybin completely abolished head-twitch responses in mice, it did not
block psilocybin-induced structural plasticity (Shao et al., 2021). These findings indicate that
psychedelics’ mechanism of action may be independent of 5-HT2AR activation. Nonetheless, the
extent of 5-HT2A receptor involvement in mediating the effects of psychedelics is an ongoing
discussion that warrants further research.
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Figure 2: Copyright © 2019 Silvia Muttoni et al. From “Classical psychedelics for the treatment
of depression and anxiety: A systematic review,” by S. Muttoni, M. Ardissino, and C. John, 2019,
Journal of Affective Disorders, Volume 258. Diagram of the multiple neurobiological
mechanisms mediating psychedelics’ antidepressant and anxiolytic effects, as a result of
serotonin (5-HT) receptor agonism.

Assessing Psychedelic Action with Behavioral Models
The use of animal models can provide valuable insight into better understanding various
physiological and behavioral processes in vivo. However, when studying neuropsychological
effects, there may be certain limitations to animal models, such as varied drug dose regimens,
differing sensory systems, and an inability to measure subjective experiences. Nevertheless,
models exhibiting effects analogous to human behavioral responses induced by psychedelics
may be beneficial in elucidating anatomical and molecular pathways underlying these behaviors
(Hanks & González-Maeso, 2013). Five behavioral models of hallucinogenic drug action were
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the focus of the present study: head-twitch response, locomotor activity, novel object
recognition, light-dark box preference, and forced swim test.

Head-Twitch Response
The head-twitch response (HTR) is a rapid side-to-side rotational head movement that
occurs in rodents as an acute response to serotonergic hallucinogens and other 5-HT2AR agonists
(Canal & Morgan, 2012). Typically, mice will initiate a head twitch while balanced on their hind
paws or in a quadruped stance, with the body slightly hunched back and head extended forward.
Over the course of an HTR, the trunk and neck progressively elongate, with the head
increasingly extending away from the body. Movement during head twitches is often confined to
the neck and does not involve the torso. Although multiple receptors and neurotransmitter
systems can induce or regulate HTR, many studies have confirmed that this behavior is
specifically linked to activation of 5-HT2AR (Halberstadt & Geyer, 2013a). In fact, research has
shown that head-twitch frequency abruptly increases when rodents are given 5-HT2AR agonists
like the psychedelic DOI (Canal & Morgan, 2012). Furthermore, HTR is blocked by selective 5HT2AR antagonists and is absent in 5-HT2AR KO mice (González-Maeso et al., 2007). Due to
this specificity, HTR is often used as an animal behavioral assay for 5-HT2AR activation and
hallucinogenic effects.
There are several methods used to assess HTR in the laboratory setting. The more
common method involves a trained rater directly observing the animals and counting the number
of head twitches. Alternatively, the animals are recorded with a video camera and their behavior
is assessed offline. Both methods may be subject to inter-rater variability, and neither is feasible
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for behavioral studies requiring very long durations. However, de la Fuente Revenga et al.
(2019) recently developed a magnetometer-based HTR detection system that provides a highthroughput assay and offers high sensitivity and specificity. In this procedure, mice are
anesthetized and a small neodymium magnet is surgically implanted on the cranial surface. After
a brief recovery period, the mice are placed in glass beakers wrapped with magnet wire. When
coil voltage amplification and Fourier analysis are complete, individual HTRs are identified by
manually searching for sinusoidal wavelets that meet certain criteria indicating rapid rotational
head movement (de la Fuente Revenga et al., 2019).

Locomotor Activity
The open field test (OFT) was initially developed by American psychologist Calvin Hall
in 1934 as a test to measure emotionality in rodents (Seibenhener & Wooten, 2015), and is now
used as a common measure of general activity and exploratory behavior. It allows for the
measurement of various qualitative and quantitative aspects of movement, including: total
distance, movement along the walls (thigmotaxis) relative to center, distance moved over
different time periods, hole-poking, freezing, and rearing. In the present study, horizontal activity
and time spent in the center and periphery relative to total time were used as parameters of
locomotor activity. OFT is also often used to assess the stimulant, sedative, or toxic effects of
pharmacological substances. Typically, the open field apparatus is circular, square, or
rectangular in shape with surrounding walls to prevent the animal’s escape. In early studies, the
OFT traditionally would last a short duration (between 2 and 10 minutes), mainly due to the
method of having to manually acquire data. However, more recent approaches permit a much
higher throughput and longer periods of monitoring. Examples include video recording and the
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use of software that tracks movement by the number of infrared beam breaks (Gould et al., 2009,
pp. 1-3).
Interestingly, hallucinogenic substances used in OFT assays have had varying effects on
locomotor and exploratory behavior in rodents. When assessed acutely in rats, Krebs-Thomson et
al. (1998) found psychedelics like DOI and LSD to decrease the amount of locomotor activity
and increase avoidance of the central portion of the open field. In mice, acute effects of
psychedelics involve a reduction in the amount of investigatory behavior (i.e. rearing and holepoking). However, low to moderate doses produce a delayed increase in distance traveled while
high doses reduce activity at the beginning of testing (Halberstadt et al., 2013b). When the
effects of hallucinogens are assessed post-acutely, total exploratory distance remains unchanged
relative to controls (de la Fuente Revenga et al., 2021).

Novel Object Recognition
Novel object recognition (NOR) is commonly used to investigate learning and memory in
rodents. It was originally described by Ennaceur and Delacour (1988) and tested on rats, but has
since been successfully adapted for mice. NOR is relatively fast and efficient, and relies on as
few as three sessions: habituation to the arena, training, and testing. Training entails visual
exploration of two identical objects, and testing involves replacing one of the previously
explored objects with a novel one (Lueptow, 2017). Rodents’ preference for a novel object
indicates that a representation of the familiar object exists in memory (Ennaceur, 2010). One of
the main advantages of NOR is its reliance on rodents’ natural proclivity for exploring novelty.
Moreover, there is no need for positive or negative reinforcement nor numerous training sessions
to motivate behavior, and it requires significantly less time than other memory tests (i.e. Morris
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water maze or Barnes maze). Additionally, it can be modified to assess different phases of
learning and memory, such as acquisition, consolidation, or recall. The versatility of NOR allows
for the study of different pharmacological agents that disrupt or enhance memory (Lueptow,
2017).
Multiple studies have documented the acute and post-acute effects of psychedelics on
NOR. In one study performed six days after injection, a single dose of LSD was found to
produce an increase in exploratory time for the novel object when compared to saline controls.
This preference was significant for young (2 months) and adult (9 months), but not old (12-18
months), rats (Cini et al., 2019). In another study testing NOR 20 min after injection, rats given
either saline or psychedelic exhibited a significant increase in exploration time for the novel
object relative to the familiar one. However, there was no significant difference in novel object
exploratory preference between these groups (Wojtas et al., 2021). In mice, both DOI and saline
produced significant increases in novel object exploration relative to the familiar object 24 hrs
post-injection. However, there was no difference in exploratory preference between both cohorts
(de la Fuente Revenga et al., 2021).

Light-Dark Box Preference
The light-dark test is based on both rodents’ innate aversion to brightly illuminated areas
and on their spontaneous exploratory behavior in response to mild stressors, such as a novel
environment and light. When exposed to a novel environment, a natural conflict arises between
the tendency to explore and an initial tendency to avoid the unfamiliar. In the light-dark box, a
square apparatus is equally divided into dark and light compartments with a small opening
connecting both sides. This assay can be used to examine the anxiogenic or anxiolytic properties
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of different pharmacological substances. For instance, a drug-induced increase in behaviors in
the white (light) relative to the dark compartment reflects anxiolytic activity. In the first lightdark studies, photocells across the partition were used to detect transitions between the two areas.
Later studies relied on human observers to document transitions and the amount of time spent on
each side from video recordings. A more modern technique involves computer-controlled
detection systems equipped with infrared beam sensors. Here, infrared beam interruptions are
automatically recorded and used to measure different parameters, such as locomotion, rearing,
time spent in light and dark zones, and shuttle crossings between zones (Bourin & Hascoët,
2003).
Psychedelics have been found to exert differing effects on the light-dark behavior of
rodents. In one study by Wojtas et al. (2021) measuring acute effects, both rats given control or
the psychedelic 25B-NBOMe spent a longer time in the dark as opposed to the light
compartment. However, the time spent in the dark zone was longer and statistically significant in
rats treated with the psychedelic. Likewise, the time spent by all animals in the light zone was
shorter and specifically decreased in the rats given 25B-NBOMe relative to controls. These
effects were dose-dependent, with higher doses of psychedelic having a more significant impact
on light-dark exploratory behavior compared to the control group (Wojtas et al., 2021). Another
study in mice showed that the psychedelic DOI had no statistically significant post-acute effect
on time spent in the light zone when compared to mice given vehicle (de la Fuente Revenga,
2021).

Forced Swim Test
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The forced swim test (FST), sometimes called the Porsolt swim test, was initially
developed for rats and later modified for mice (Porsolt et al., 1978). It is one of the most
commonly used assays to measure behavioral despair and passivity as a model of depression-like
behavior, and it involves placing the rodent in an inescapable container filled with water. The
FST operates on the assumption that when placed in a container with water, an animal will first
attempt to escape but will eventually exhibit immobility. This immobility may be considered to
reflect a measure of behavioral despair. Several other parameters can also be measured, such as
the time spent struggling/climbing or swimming. Typically, the test duration is 6 minutes long
and behavioral coding occurs during the last 4 minutes (mice) or 5 minutes (rats). This test has
been extensively used because it exposes the animals to stress, which has been shown to have a
role in the tendency for major depression. The main advantage of FST is that it is relatively
simple to perform and the results are easily and quickly analyzed. Furthermore, it has a high
predictive validity due to its sensitivity to a broad range of antidepressant drugs (YankelevitchYahav et al., 2015).
The effects of psychedelic substances on FST have been well-documented. One study
showed that N,N-dimethyltryptamine (DMT), the principle hallucinogenic component of
ayahuasca, significantly reduced immobility and increased swimming times in rats relative to the
control group (Cameron et al., 2018). Another study found that both psilocybin and LSD
produced significant reductions in immobility time and increased swimming time, with LSD also
increasing the climbing time relative to rats given saline (Hibicke et al., 2020). In mice, DOI
significantly reduced the immobility time compared to controls, indicating antidepressant-like
effects (de la Fuente Revenga et al., 2021).
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Rationale for This Study
While psychedelics have been shown to produce long-lasting antidepressant and
anxiolytic effects, it is still an open question on whether or not these effects are 5-HT2A
receptor-dependent. First, I aimed to take a closer look at the psychedelic psilocybin’s acute
effects on head-twitch response (HTR) as well as its post-acute effects on the following
behavioral models: locomotor activity, novel object recognition (NOR), light-dark box
preference, and forced swim test (FST). I hypothesized that psilocybin will acutely increase the
number of head twitches and post-acutely decrease immobility time in the FST compared to
controls, while post-acute behaviors in the locomotion, NOR, and light-dark box assays will
remain unaffected. Since psilocybin was found to have a significant effect on immobility time in
the FST, my next goal was to determine if the 5-HT2AR played a necessary role in mediating
these post-acute effects using the 5-HT2AR-specific antagonist volinanserin (M100,907). I
hypothesized that mice given M100,907 shortly prior to injection with psilocybin will exhibit
greater immobility (or behavioral despair) compared to mice who were administered psilocybin
alone. With this study, my hope was to better understand not only the post-acute antidepressantlike and anxiolytic effects of psilocybin, but also to examine whether or not these effects are in
fact 5-HT2AR-dependent. The results from this study can be used a model for future studies to
explore the magnitude of the 5-HT2A receptor’s role in mediating different psychedelics’ postacute effects.
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Chapter 2: Materials and Methods
Animals
Adult (10-20 weeks old) male WT C57BL/6 mice were used for all head-twitch response,
locomotive function, novel object recognition, light-dark box preference, and forced-swim tests.
Mice were ordered from Jackson Laboratory. All mice were housed in a vivarium in cages with
up to four mice total on a 12-hour light/dark cycle at 23°C with food and water ad libitum,
except during behavioral testing (always during the light cycle). Routine monitoring and
veterinary care were provided with the assistance of the Virginia Commonwealth University
Division of Animal Research staff. All experiments were conducted in accordance with NIH
guidelines and were approved by the Virginia Commonwealth University Institutional Animal
Care and Use Committee. All efforts were made to minimize animal suffering and the number of
animals used in these experiments.

Drugs
The IUPAC name and source of the drugs used for these procedures and experiments is
as follows: 3-[2-(dimethylamino)ethyl]-1H-indol-4-yl]dihydrogen phosphate (psilocybin) from
Usona Institute; and (R)-(2,3-dimethoxyphenyl)-[1-[2-(4-fluorophenyl)ethyl]piperidin-4yl]methanol (volinanserin or M100,907) from Sigma-Aldrich. Drugs were dissolved in 0.9%
saline and injection volumes and concentrations were determined based on body weight (0.005
mL/gram). All drugs were administered intraperitoneally (i.p.). Any indication for use of a
vehicle refers to an equivalent volume of 0.9% NaCl administered to the animal.
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Head-Twitch Response
Surgical implantation of the head-mounted magnet was performed as previously
described (de la Fuente Revenga et al., 2019). First, mice were anesthetized using 2% isoflurane.
Magnetic ear tag devices were created by attaching small, circular neodymium magnets to the
end of standard colored ear tags with superglue. The south pole was glued to the tag with the
north pole facing upwards. Ear tags were attached to the lower half of both ears, close to the head
and not obstructing the ear canal. Mice underwent a week-long recovery period prior to testing.
As outlined by de la Fuente Revenga et al. (2019), data collection for automated headtwitch detection was performed in non-overlapping ~500-turn enameled wire (30 AWG) coiled
around plastic cylinders (11 cm diameter x 14 cm tall). The terminals of each coil were
connected to a phono preamplifier (Pyle PP444). A total of six mice could be run during one
trial, with one mouse per chamber. Mice were placed into these chambers and recorded for 30
min to measure basal activity and allow for acclimation to the chamber. Mice were then
removed, injected with either psilocybin (1 mg/kg, i.p.) or vehicle, immediately placed again into
chambers, and monitored for 90 min. The chambers were cleaned with 1% Roccal-D in between
sessions. While in the chambers, head and body movements were amplified and recorded as
changes in voltage occurring with varying frequencies. The amplified signal output was recorded
with MATLAB software version R2018b (MathWorks). These wavelet signals were transformed
into unipolar peaks that were then identified as true HTR events based on certain criteria
regarding frequency, duration, and intensity of the peak. After completion of the experiment,
mice were returned to their home cages.
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Locomotor Activity
Locomotor activity was monitored as previously described (de la Fuente Revenga et al.,
2021). Animals were injected with either psilocybin (1 mg/kg, i.p.) or vehicle and immediately
returned to their home cage. Evaluation of locomotor activity was conducted 24 hrs after drug
administration. Mice were allowed to acclimate to the behavioral room for 1 hr prior to
monitoring their individual locomotor activity. Mice were placed in individual locomotion
chambers (25 x 25 x 20 cm open-field Plexiglas cages) with an automated detection system
composed of 16 infrared light beam rays in the X and Y axes. A total of four mice could be run
during one trial, with one mouse per chamber. Each trial lasted 90 min. These chambers were
connected to a computerized three-dimensional activity monitoring system, Fusion (v5.3;
Omnitech Electronics Inc.), that interpolates the animal’s activity from interruption of infrared
beams traversing the different planes of space. These interruptions are detected and can be
quantified into different metrics, such as horizontal/vertical activity, rearing, and total distance.
Horizontal activity was measured as the collapsed amount of beam interruptions in the X-Y
planes in 5-min increments. Time spent in the central (defined as the center 8 x 8 square matrix)
and peripheral (defined as the exterior 4 x 16 and 16 x 4 matrices) zones of the apparatus relative
to the total test duration were also quantified. The chambers were cleaned with 1% Roccal-D in
between sessions. After completion of the experiment, mice were returned to their home cages.

Novel Object Recognition
Study was conducted as previously described (de la Fuente Revenga et al., 2021). The
testing arena consisted of an opaque rectangular plastic container with an open top (32 x 20 x 23
cm). The objects used (tissue culture flasks filled with wood chips and opaque white light bulbs)
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were of comparable volume and height (approx. 10 cm). Objects were attached to the bottom of
the container (using double-sided tape) 10 cm away from the walls. Both the objects and
chambers were thoroughly cleaned with diluted ethanol between tests to remove olfactory cues.
Preference for a novel object, compared to a familiar one, was tested 24 hrs after mice received
either psilocybin (1 mg/kg, i.p.) or vehicle. Mice were allowed to acclimate to the behavioral
room for the duration of the whole session (at least 1 hr prior to testing). A total of four mice
could be evaluated during each test, with one mouse per container.
The test consisted of three stages: a 20 min habituation to the field; a 5 min acquisition
trial in which two identical objects were present in the field; and a 5 min recognition trial in
which one of the identical objects was replaced with a novel one. All stages were separated by 5
min during which the animals were returned to their home cage. Object exploration was defined
as the animal licking, sniffing, or touching the object with forepaws while sniffing. Climbing an
object was not considered in the exploration time. The exploration time for each side during
acquisition (same object on both sides) and the exploration time for the novel object during
recognition was assessed via digital video camera recordings. The exploratory preference for the
novel object was calculated as the percentage of total exploratory time spent exploring the novel
object during the recognition stage. Place preference was controlled by alternating the position of
the novel object between left and right during the recognition stage. After completion of the
experiment, mice were returned to their home cages.

Light-Dark Box Preference
Animals were injected with either psilocybin (1 mg/kg, i.p.) or vehicle and immediately
returned to their home cage. Preference for light or dark environment was studied 24 hrs after
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drug administration using a commercial open-field activity box in which space is equally divided
into light and dark areas (25 x 12 x 20 cm each) connected through a small (5 x 5 cm) opening
(Pais et al., 2019). Mice were allowed to acclimate to the behavioral room for 1 hr prior to
testing. Four mice could be run during a trial, with one mouse per chamber. Each trial lasted 90
minutes. The boxes were connected to Fusion, which inferred animal activity and position from
interruptions to infrared beams traversing the different spatial planes. The study monitored their
preference for each area (light/dark). Time spent during the first three 5-min fractions and total
time spent in the light zone were quantified. The chambers were cleaned with 1% Roccal-D in
between sessions. After completion of the experiment, mice were returned to their home cages.

Forced Swim Test
Assay occurred as previously described (de la Fuente Revenga et al., 2021). 2 L (12.5 cm
diameter x 21 cm height) beakers were two-thirds filled with water (approx. 23ºC). Mice were
carefully introduced to the containers while being held by the tail so that the head would remain
above water during the immersion. A habituation FST was conducted 24 hrs prior to drug
injection. Procedure was conducted 24 hrs after injection with either psilocybin (1 mg/kg, i.p.) or
vehicle. This protocol was repeated for two additional studies: FST 24 hrs post-injection with
either M100,907 (0.5 mg/kg, i.p.) administered 15 min prior to psilocybin (1 mg/kg, i.p.) or
vehicle alone; and FST 24 hrs post-injection with either M100,907 (0.5 mg/kg, i.p.) or vehicle.
Mice were acclimated to the behavioral room for the duration of the whole session (at least 1 hr
prior to testing). There was at least a one-week period between each FST to ensure drug washout.
Sessions were recorded on a digital video camera and immobility, climbing, and
swimming times were scored during the last 4 min of the 6 min session. Immobility was defined
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as passive floating with no additional activity except that needed to maintain the animal’s head
above water level. Climbing was defined as vertical movements of the forelimbs against the
walls. Swimming was defined as horizontal movements of the fore- or hindlimbs across the
water surface (Bogdanova et al., 2013). Three mice could be evaluated during each trial, with
one mouse per beaker. Beakers were cleaned with 1% Roccal-D and refilled with water in
between sessions. After each trial, mice were allowed to dry in a paper towel-lined empty cage
placed atop a heating pad before being returned to their home cages.

Statistical Analysis
Data from the HTR test was first processed using MATLAB software. Data from the
locomotion and light-dark box studies were analyzed with Fusion software. Data from Fusion for
each of these studies was compiled into a large data set that measured activity based on several
different metrics. Horizontal activity count and time spent in central and peripheral zones
(relative to total duration) were selected as measures of locomotor activity. Time duration in the
light zone was used as a metric of light-dark preference. Data from NOR and FST were collected
from digital video camera recordings. Animals were randomly allocated into the different
experimental groups.
Results from all studies were inputted into GraphPad Prism software version 9 for
graphing and statistical analysis. Statistical significance of experiments involving time courses
and two treatments was assessed by two-way ANOVA. When appropriate, Bonferroni multiple
comparisons post hoc test was used for additional statistical analysis to examine several points of
comparison. Statistical significance of experiments involving two groups was assessed using
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student’s unpaired t-test. The level of significance chosen was p < 0.05. All data are presented as
mean ± standard error of the mean (S.E.M.).

23

Chapter 3: Results
Effect of Psilocybin on HTR
Male WT C57BL/6 mice were prepared for the head-twitch experiment by attachment of
magnet-implanted ear tags. After a week-long recovery process, they were first measured for a
30-min basal HTR. Animals were then injected with vehicle (0.9% saline) or psilocybin (1
mg/kg) and replaced into the chambers for 90 min. Data was collected in 15-min fractions and in
a 30-min block following an initial 15-min habituation period.
During the 15-min fractions (Fig. 3A), a significant difference in head-twitch counts was
observed between the vehicle and psilocybin groups (two-way ANOVA: F (1, 14) = 13.90, p =
0.0022) with an effect of time (two-way ANOVA: F (1.878, 26.30) = 28.28, p < 0.0001). There
was a significant time x drug interaction (two-way ANOVA: F (7, 98) = 22.77, p < 0.0001).
Bonferroni post hoc analysis showed significance particularly at the 15-min (p = 0.0050) and 30min (p = 0.0300) time points. Composite head-twitch counts (Fig. 3B) between vehicle and
psilocybin groups were also significant (student’s unpaired t-test: t = 4.941, df = 14, p = 0.0002).
These findings verified that the dose of psilocybin (1 mg/kg) was biologically active and justified
its use in subsequent assays.
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A.

B.

Figure 3: Effect of psilocybin on head-twitch response in male WT C57BL/6 mice. Mice were
administered vehicle or psilocybin (1 mg/kg) 24 hrs prior to testing. Number of HTR events
shown in (A) 15-min fractions (30 min baseline + 90 min testing), two-way ANOVA with
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Bonferroni post hoc test; and (B) a 30-min block after 15 min of habituation, student’s unpaired
t-test. n = 8 for each group. Data are presented as group mean ± S.E.M. (** p < 0.01, *** p <
0.001, **** p < 0.0001)

Effect of Psilocybin on Locomotor Activity
Male WT C57BL/6 mice were administered vehicle (0.9% saline) or psilocybin (1
mg/kg) 24 hrs prior to testing and were acclimated to the behavioral room for at least 1 hr before
monitoring individual locomotor activity. Each mouse was placed in an individual Plexiglas
locomotion chamber with an automated detection system for a duration of 90 min. Data was
collected as horizontal activity (beam interruptions in 5 min fractions), total horizontal activity,
and percent of total time spent in the central and peripheral zones.
During the 5 min fractions (Fig. 4A), there was no significant difference observed
between the vehicle and psilocybin groups (two-way ANOVA: F (1, 14) = 0.04884, p = 0.8283).
While time had a significant effect (two-way ANOVA: F(7.140, 99.95) = 22.73, p < 0.0001),
there was no significant time x drug interaction (two-way ANOVA: F(17, 238) = 0.5044, p =
0.9496). Similarly, during the total horizontal activity (Fig. 4B), there was no significance
between both groups (student’s unpaired t-test: t = 0.2210, df = 14, p = 0.8283). Additionally, no
difference was observed when assessing time spent in the center and in the periphery (student’s
unpaired t-test: t = 0.9684, df = 14, p = 0.3493) relative to total time (Figs. 4C-D, respectively).
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Figure 4: Effect of psilocybin on locomotor activity in male WT C57BL/6 mice. Mice were
administered vehicle or psilocybin (1 mg/kg) 24 hrs prior to testing. (A) Horizontal activity
measured in 5-min fractions, two-way ANOVA with Bonferroni post hoc test. (B) Total
horizontal activity; (C) Center-to-total time; and (D) Periphery-to-total time analyzed with
student’s unpaired t-test. n = 8 for each group. Data are presented as group mean ± S.E.M. (n.s.
= not significant)

Effect of Psilocybin on NOR
Male WT C57BL/6 mice were administered vehicle (0.9% saline) or psilocybin (1
mg/kg) 24 hrs prior and were acclimated to the behavioral room for at least 1 hr before testing.
Each mouse was placed in an opaque rectangular plastic container with an open top, and objects
of comparable height and volume were used. Testing consisted of three stages: habituation to the
arena, acquisition (using two identical objects), and recognition (one familiar object replaced
with a novel one). Exploratory preference was calculated for both the acquisition and recognition
stages for both groups of mice.
As shown in Fig. 5, there was a significant difference in exploratory preference between
the acquisition and recognition stages for both experimental groups (two-way ANOVA: F(1,10)
= 102.7, p < 0.0001), indicating greater preference for the novel object compared to the familiar
one. However, there was no significant effect of the drug (two-way ANOVA: F(1, 10) = 1.312, p
= 0.2787) nor time x drug interaction (two-way ANOVA: F(1, 10) = 0.9749, p = 0.3468).
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Figure 5: Effect of psilocybin on novel object recognition in male WT C57BL/6 mice. Mice were
administered vehicle or psilocybin (1 mg/kg) 24 hrs prior to testing. Exploratory preference (%)
for each side during acquisition and for the novel object during recognition was assessed from
digital camera recordings. n = 6 for each group. Data are presented as group mean ± S.E.M.
Two-way ANOVA with Bonferroni post hoc test (**** p < 0.0001, n.s. = not significant).

Effect of Psilocybin on Light-Dark Box Preference
Male WT C57BL/6 mice were administered vehicle (0.9% saline) or psilocybin (1
mg/kg) 24 hrs prior and acclimated to the behavioral room for at least 1 hr. Mice were placed in
individual chambers and light-dark activity was monitored for 90 min. Each chamber was
equally divided into light and dark zones with a small opening connecting both areas. Data was
collected for the first three 5 min fractions and for the total 90 min duration.
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During the first three 5 min fractions (Fig. 6A), psilocybin did not have a significant
effect on time spent in the light zone (two-way ANOVA: F(1, 10) = 1.864, p = 0.2021).
Although time had a significant effect (two-way ANOVA: F(1.444, 14.44) = 17.84, p = 0.0003),
there was no significant time x drug interaction (two-way ANOVA: F(2, 20) = 0.004993, p =
0.9950). Likewise, there was no significant difference in total exploratory time spent in the light
zone (Fig. 6B) between vehicle and psilocybin groups (student’s unpaired t-test: t = 1.479, df =
10, p = 0.1698).
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A.

B.

Figure 6: Effect of psilocybin on light-dark box preference in male WT C57BL/6 mice. Mice
were administered vehicle or psilocybin (1 mg/kg) 24 hrs prior to testing. Time (s) spent in light
zone shown (A) in the first three 5-min fractions of testing, two-way ANOVA with Bonferroni
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post hoc test; and (B) over the total 90-min of testing, student’s unpaired t-test. n = 6 for each
group. Data are presented as group mean ± S.E.M. (n.s. = not significant)

Effect of Psilocybin on FST
Male WT C57BL/6 mice underwent a habituation FST 24 hrs prior to administration of
either vehicle (0.9% saline) or psilocybin (1 mg/kg). Drugs were injected 24 hrs prior and
animals were acclimated to the behavioral room for at least 1 hr before conducting the recorded
FST. Mice were placed into individual beakers that were ~2/3 filled with water and immobility,
climbing, and swimming times were scored during the last 4 min of the 6 min test duration.
Mice in the psilocybin group had a significantly lower immobility time (Fig. 7A;
student’s unpaired t-test: t = 2.462, df = 10, p = 0.0335) and higher climbing time (Fig. 7B;
student’s unpaired t-test: t = 3.205, df = 10, p = 0.0094) relative to the controls. There was no
significant difference in swimming time (Fig. 7C) between the two groups (student’s unpaired ttest: t = 1.915, df = 10, p = 0.0845).
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Figure 7: Effect of psilocybin on forced swim test in male WT C57BL/6 mice. Mice were
administered vehicle or psilocybin (1 mg/kg) 24 hrs prior to testing. (A) Immobility; (B)
Climbing; and (C) Swimming time (s) analyzed with student’s unpaired t-test. n = 6 for each
group. Data are presented as group mean ± S.E.M. (* p < 0.05, ** p < 0.01, n.s. = not
significant)

Effect of M100,907 + Psilocybin on FST
I hypothesized that psilocybin’s effects on FST are 5-HT2AR-dependent, and that these
effects would be diminished with a selective receptor antagonist. To test this, the 5-HT2Aspecific antagonist volinanserin (M100,907) was administered to mice 15 min prior to injection
with psilocybin. Male WT C57BL/6 mice underwent a habituation FST 24 hrs prior to
administration of either vehicle (0.9% saline) or M100,907 (0.5 mg/kg) + psilocybin (1 mg/kg).
Drugs were injected 24 hrs prior and animals were acclimated to the behavioral room for at least
1 hr before conducting the recorded FST. Mice were placed into individual beakers that were
~2/3 filled with water and immobility, climbing, and swimming times were scored during the last
4 min of the 6 min test duration.
There was no significant difference in immobility (Fig. 8A; student’s unpaired t-test: t =
0.02917, df = 10, p = 0.9773), climbing (Fig. 8B; student’s unpaired t-test: t = 0.0096, df = 10, p
= 0.9925), or swimming time (Fig. 8C; student’s unpaired t-test: t = 0.03077, df = 10, p =
0.9761) between both groups.
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Figure 8: Effect of M100,907 + psilocybin on forced swim test in male WT C57BL/6 mice. Mice
were administered vehicle or M100,907 (0.5 mg/kg) 15 min prior to psilocybin (1 mg/kg), 24 hrs
prior to testing. (A) Immobility; (B) Climbing; and (C) Swimming time (s) analyzed with
student’s unpaired t-test. n = 6 for each group. Data are presented as group mean ± S.E.M. (n.s.
= not significant)

Effect of M100,907 on FST
Next, I wanted to see if M100,907 alone would have an effect on immobility, climbing,
or swimming time. Male WT C57BL/6 mice underwent a habituation FST 24 hrs prior to
administration of either vehicle (0.9% saline) or M100,907 (0.5 mg/kg). Drugs were injected 24
hrs prior and animals were acclimated to the behavioral room for at least 1 hr before conducting
the recorded FST. Mice were placed into individual beakers that were ~2/3 filled with water and
immobility, climbing, and swimming times were scored during the last 4 min of the 6 min test
duration.
There was no significant difference in immobility time (Fig. 9A; student’s unpaired t-test:
t = 1.325, df = 9, p = 0.2179) nor in swimming time (Fig. 9C; student’s unpaired t-test: t = 1.204,
df = 9, p = 0.2594) between the vehicle and M100,907 groups. However, mice given M100,907
had a significantly lower climbing time (Fig. 9B) relative to controls (student’s unpaired t-test: t
= 4.980, df = 9, p = 0.0008).
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Figure 9: Effect of M100,907 on forced swim test in male WT C57BL/6 mice. Mice were
administered vehicle or M100,907 (0.5 mg/kg) 24 hrs prior to testing. (A) Immobility; (B)
Climbing; and (C) Swimming time (s) analyzed with student’s unpaired t-test. n = 5 for vehicle
and n = 6 for M100,907. Data are presented as group mean ± S.E.M. (*** p < 0.001, n.s. = not
significant)
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Chapter 4: Discussion
Psychedelics have been shown to induce antidepressant and anxiolytic effects, indicating
their potential as promising alternatives for the management of depression and anxiety.
Importantly, many studies have found the 5-HT2A receptor to play a critical role in mediating
these effects. For instance, de la Fuente Revenga et al. (2021) showed the 5-HT2A receptor to
mediate DOI’s acceleration of fear extinction using 5-HT2AR WT and KO male mice. Another
study using male rats found that DOI- and mescaline-induced, but not LSD- nor psilocybininduced, intracranial self-stimulation (ICSS) depression was blocked with the 5-HT2AR-specific
antagonist volinanserin (M100,907) (Jaster et al., 2022). These varying results on ICSS
depression blockade across different psychedelics underscore the need for additional work
regarding the specific molecular target responsible for the effects of psychedelics. On the other
hand, a few studies suggest that 5-HT2AR involvement is not necessary for psychedelic-induced
behavioral and electrophysiological changes (Hesselgrave et al., 2021; Shao et al., 2021). The
purpose of this study was to examine the post-acute effects (i.e. 24 hrs after injection) of the
psychedelic psilocybin on models of anxiety, recognition memory, and depression-like behavior.
Additionally, I wanted to determine whether psilocybin’s effects on behavioral despair in the
FST depend on 5-HT2A receptor activation by employing the selective antagonist M100,907.
As expected, psilocybin acutely induced a highly significantly number of head-twitch
events compared to the vehicle group. This finding confirmed that the dose of psilocybin used (1
mg/kg) was indeed a biologically active dose and justified its use in our subsequent behavioral
tests measuring psilocybin’s post-acute effects. However, in our assays of locomotion,
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psilocybin- and vehicle-treated mice showed no difference in horizontal activity nor in the time
spent in the center and periphery of the open-field relative to the total duration. Likewise,
compared to their control counterparts, mice administered psilocybin did not exhibit significant
differences post-acutely in the time spent exploring the light zone in the light-dark box
preference test. Additionally, while psilocybin and control mice showed strong preference for the
novel object over the familiar object in the NOR assay, the exploratory preference between the
two experimental groups was not significant. Together, these results indicate that psilocybin did
not affect behaviors of anxiety or recognition memory when assessed post-acutely. This is
consistent with previous studies using the phenethylamine psychedelic DOI, which show that
behaviors in models of anxiety and recognition memory remain unchanged at least 24 hrs after
administration of a single dose (de la Fuente Revenga et al., 2021).
Interestingly, psilocybin was found to significantly reduce immobility time and increase
climbing/struggling time in the FST. This finding implies that a single dose of psychedelic
reduces behavioral despair as a model of depression-like behavior at least 24 hrs after its
administration. Even more surprisingly, administration of the 5-HT2A-specific antagonist
M100,907 (0.5 mg/kg) 15 min prior to psilocybin in subsequent FST assays abolished the effects
of psilocybin alone on immobility and climbing times. This result indicates that psilocybin’s
antidepressant-like effects are in fact dependent on 5-HT2A receptor activation, in contrast to
prior studies claiming that psychedelic-induced behavioral changes do not require 5-HT2A
involvement (Hesselgrave et al., 2021; Shao et al., 2021). Furthermore, the FST with M100,907
alone revealed a significantly lower climbing time in the group receiving antagonist, while the
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immobility and swimming times between the control and experimental groups were not
significant.
Nevertheless, the present study had several potential limitations. These included the use
of only one strain and sex of mice. Studies have shown that different strains of mice have
varying responses to drugs in aspects such as locomotor activity and prepulse inhibition (van den
Buuse, 2010). Thus, future studies may incorporate strains such as 129Sv or BALB/c to better
characterize the hallucinogenic effects of psychedelics across a wider spectrum of genetic
backgrounds. Additionally, this study only utilized male mice. Intriguingly, studies including
female mice have found that psychedelics like DOI have different effects on startle amplitude
and percent of prepulse inhibition compared to males (Vohra et al., 2021). Another study has
shown that DMT induces distinct changes in neuronal structure in female, but not male, rats,
such as reduced dendritic spine density (Cameron et al., 2019). Going forward, the inclusion of
female mice could unveil sex-specific behavioral responses that were not observed in the present
study. Another limitation of this study was that the mice used in the FST assays were not drugnaïve. That is, mice receiving psychedelic in the first FST received vehicle in the second FST,
but were again administered drug in the third FST. Since the mice were not drug-naïve, this may
explain the varying baseline of the vehicle group in the FST parameters tested. Furthermore,
each mouse underwent the FST more than once (since there were three separate assays), which
may have resulted in learning. This, along with the lack of drug-naivety, could have also
contributed to the altering baseline values amongst the different FST assays. These limitations
can be rectified in future studies by ensuring that each mouse only undergoes the FST once, and
by using separate mice for each experimental group (so that all mice used are drug-naïve). Doing
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so may reveal differences between the vehicle and experimental groups that were not present
otherwise in this study.
In regard to future directions, there are several avenues that warrant further exploration.
Given the results of the FST, which showed the necessity of 5-HT2A activation in order to
induce psilocybin’s effects on behavioral despair as a model of depression-like behavior, it
would be particularly interesting to carry out these behavioral assays in mice with WT 5-HT2A
compared to mice with null or mutant 5-HT2A. While HTR is strongly correlated with 5-HT2A
receptor activation and has been shown to be significantly reduced or absent in null-mutant mice
(González-Maeso et al., 2003), additional studies could better examine the extent of 5-HT2A
involvement in mediating psychedelics’ effects in models of anxiety, recognition memory, and
depression-like behavior. Future studies could also investigate the role of 5-HT2A in mediating
psychedelics’ effects on dendritic spine density. Structural and functional modification of
dendritic spines are central to brain plasticity. Generally, increased synaptogenesis and
functional plasticity are highly correlated with the size and shape of a dendritic spine (de la
Fuente Revenga et al., 2021). Clinical studies have demonstrated that depression is associated
with a reduction in synaptic density in the frontal cortex and other brain regions regulating mood
and anxiety (Savalia et al., 2021). Very interestingly, Ly et al. (2018) found that a single dose of
DMT significantly increased the dendritic spine density of cortical pyramidal neurons 24 hrs
after administration. Further research would allow for a more comprehensive understanding of
the degree of 5-HT2AR involvement in psychedelic-induced behavioral and electrophysiological
changes. Additionally, the present study only looked at the effects of psilocybin on the above-
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mentioned behavioral models. Including a wider variety of hallucinogens, such as LSD and
DMT, would permit a better evaluation and comparison of the behavioral effects of different
psychedelics. Future directions may also measure the behavioral outcomes of acute vs. chronic
doses, and could thus determine the dose-dependent effects of psychedelics.
Overall, this study not only reveals a post-acute effect of psilocybin on behavioral despair
as a model of depression-like behavior, but also that this antidepressant-like activity is dependent
on 5-HT2A receptor activation. While there was no significant post-acute effect on models of
anxiety or recognition memory, it highlights the need for future studies that expand on the dosedependent effects of psychedelics on these behaviors. More importantly, this study sheds light on
the central role of the 5-HT2AR in mediating psychedelics’ effects and opens the door for further
research on the extent of its involvement through the use of genetically modified animal models.
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